Due to geopolitical tensions, AstraZeneca is considering spinning off its operations in China and listing a separate division in Hong Kong. However, there are no confirmations from the company itself and it may ultimately just remain a rumor.
In their results presentation, they mentioned 10 potential blockbuster chances related to their success with novel medicines. Since then, Tagrisso's phase three trials for the treatment of non-small cell lung cancer, the most prevalent kind of lung cancer, have shown promising results. With 38% of AstraZeneca's projected sales coming from the treatment of cancer, this industry is already the company's strongest.
Farxiga has also received US approval as a therapy for heart failure. It has managed to improve the performance of the cardiovascular, renal, and metabolism [CVRM] division, which is the second largest contributor to the company's revenues and has already demonstrated strong growth of 32% YoY in Q1 2023. This is encouraging for the company's growth in general, given that the US accounts for 42% of its overall revenues and is its largest market.
Without a doubt, AstraZeneca continues to be a market-leading pharmaceutical business with expanding revenues, steady earnings, and a promising therapy pipeline. This is further supported by its estimate for 2023, which anticipates solid revenue and profitability growth.
This suggests that it can hold investors in good stead over the long term. It has already proven itself in the past. Over the past five years, the asthas nearly doubled investors' money despite all the ups and downs that have occurred in between.
Leave a Reply